SMCI’s interview/presentation featuring Dr. Klimas provides a call to arms for fundraising advocates. NIH's funding inequity is highlighted in Jørgen Jelstad’s “The chronic lack of funds for ME/CFS research:" An NIH update with dollars in millions for the years 2013 to 2018 estimates low 2018 funding: MS--$77m; Arthritis--$193m ; Lupus--$76m; ME/CFS--$6m. Meanwhile, Dr. Klimas tells us: “Eight years ago...but there’s no place to go.” Our advocates claim that, based on disease burden, NIH funding for ME/CFS research should be equivalent to $188 per patient per year:" A 25-fold NIH funding increase is calculated by projecting an estimated ME/CFS Disability Adjusted Life Year (DALY) onto 2013 NIH data and using a modest prevalence estimate. It provides no compensation for past malfeasance. Burden of disease is an important factor in NIH funding decisions, along with such factors as scientific opportunity, the quality of the science and the interest of researchers. But in the final analysis, a Washington Post article reports, less NIH funding may be provided to diseases “where we blame the victim” or there is less public support.